AU2021250442A1 - Novel salmonella-based coronavirus vaccine - Google Patents

Novel salmonella-based coronavirus vaccine Download PDF

Info

Publication number
AU2021250442A1
AU2021250442A1 AU2021250442A AU2021250442A AU2021250442A1 AU 2021250442 A1 AU2021250442 A1 AU 2021250442A1 AU 2021250442 A AU2021250442 A AU 2021250442A AU 2021250442 A AU2021250442 A AU 2021250442A AU 2021250442 A1 AU2021250442 A1 AU 2021250442A1
Authority
AU
Australia
Prior art keywords
cov
sars
protein
amino acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021250442A
Other languages
English (en)
Inventor
Heinz Lubenau
Marc Mansour
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NEC OncoImmunity AS
Original Assignee
NEC OncoImmunity AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NEC OncoImmunity AS filed Critical NEC OncoImmunity AS
Publication of AU2021250442A1 publication Critical patent/AU2021250442A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2021250442A 2020-03-31 2021-03-31 Novel salmonella-based coronavirus vaccine Pending AU2021250442A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20167405 2020-03-31
EP20167405.8 2020-03-31
PCT/EP2021/058513 WO2021198376A1 (en) 2020-03-31 2021-03-31 Novel salmonella-based coronavirus vaccine

Publications (1)

Publication Number Publication Date
AU2021250442A1 true AU2021250442A1 (en) 2022-11-10

Family

ID=70110247

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021250442A Pending AU2021250442A1 (en) 2020-03-31 2021-03-31 Novel salmonella-based coronavirus vaccine

Country Status (8)

Country Link
US (1) US20230137174A1 (https=)
EP (1) EP4126022A1 (https=)
JP (1) JP2023519562A (https=)
KR (1) KR20220161444A (https=)
CN (1) CN115715198A (https=)
AU (1) AU2021250442A1 (https=)
CA (1) CA3170674A1 (https=)
WO (1) WO2021198376A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY39378A (es) * 2020-08-14 2022-01-31 Univ Wuerzburg J Maximilians Vacuna de salmonella para el tratamiento de coronavirus
CN114517205A (zh) * 2020-11-20 2022-05-20 北京震旦鼎泰生物科技有限公司 融合基因及一种重组新型冠状病毒高效免疫鼎分子dna疫苗及其构建方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060240515A1 (en) * 2003-07-21 2006-10-26 Dimitrov Dimiter S Soluble fragments of the SARS-CoV spike glycoprotein
WO2005030122A2 (en) * 2003-08-13 2005-04-07 Chiron Corporation Inactivated host cell delivery of polynucleotides encoding immunogens
CN1327900C (zh) * 2005-03-30 2007-07-25 武汉大学 一种染色体上携带病毒基因的减毒伤寒杆菌疫苗及制备方法
CA2853656C (en) 2011-12-22 2020-12-29 Vaximm Ag Method of producing high yield attenuated salmonella strains
CA3063419A1 (en) * 2017-05-15 2018-11-22 University Of Maryland, Baltimore Live salmonella typhi vectors engineered to express heterologous outer membrane protein antigens and methods of use thereof
WO2020237246A1 (en) * 2019-05-23 2020-11-26 University Of Maryland, Baltimore Live attenuated non-transmissible vaccines
US10973908B1 (en) * 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine

Also Published As

Publication number Publication date
CA3170674A1 (en) 2021-10-07
US20230137174A1 (en) 2023-05-04
WO2021198376A1 (en) 2021-10-07
JP2023519562A (ja) 2023-05-11
KR20220161444A (ko) 2022-12-06
CN115715198A (zh) 2023-02-24
EP4126022A1 (en) 2023-02-08

Similar Documents

Publication Publication Date Title
US20210290759A1 (en) Immune composition, preparation method therefor, and application thereof
CN113666990B (zh) 一种诱导广谱抗冠状病毒的t细胞疫苗免疫原及其应用
CN113151184B (zh) 基于细胞膜展示冠状病毒免疫原以诱导中和抗体的方法
JP7731670B2 (ja) ネコ白血病ウイルスワクチン
US20230174588A1 (en) A vaccine against sars-cov-2 and preparation thereof
WO2022003119A1 (en) Cross-reactive coronavirus vaccine
CA3261388A1 (en) Pharmaceutical composition to resist SARS-CoV-2 infection or a mutation thereof and a combination drug thereof
US20230137174A1 (en) Novel salmonella-based coronavirus vaccine
Lagranderie et al. A cocktail of Mycobacterium bovis BCG recombinants expressing the SIV Nef, Env, and Gag antigens induces antibody and cytotoxic responses in mice vaccinated by different mucosal routes
JP4653934B2 (ja) バクテリオファージによって仲介される免疫化方法
US20240398934A1 (en) Feline leukemia virus vaccine
WO2022105880A1 (zh) 融合基因及一种重组新型冠状病毒高效免疫dna疫苗及其构建方法和应用
Agterberg et al. Outer membrane protein PhoE as a carrier for the exposure of foreign antigenic determinants at the bacterial cell surface
JP2024520730A (ja) コロナウイルスに対するウイルス様粒子ワクチン
US20180153976A1 (en) Novel cmv pp65 targeting dna vaccine for cancer immunotherapy
KR20210123190A (ko) 지카 바이러스 백신
US20250186575A1 (en) Vaccine construct and uses thereof
CN110382518B (zh) 用于血清型a型口蹄疫病毒的嵌合疫苗
KR102646366B1 (ko) 바이러스 유사 입자를 이용한 돼지 유행성 설사병 바이러스 백신 및 이의 제조방법
Choudary et al. Enhanced immune response of DNA vaccine (VP1-pCDNA) adsorbed on cationic PLG for foot and mouth disease in guinea pigs
JP4535874B2 (ja) 肝炎に対するバクテリオファージを介する免疫
US20250197885A1 (en) Recombinant virus-like particle capsid vaccines against adenoviruses and compositions, methods, and use thereof
US20210290760A1 (en) Bacteriophage-Based Vaccines and Engineered Bacteriophage
Lavine Cytokine-assisted vaccination strategies against the bioterrorism agent Francisella tularensis